PET Imaging Combined with Fluid Biomarkers

Overview

The integration of positron emission tomography (PET) imaging with cerebrospinal fluid (CSF) and blood-based biomarkers represents a cornerstone of modern [Alzheimer's disease](/diseases/alzheimers-disease) (AD) biomarker research. This approach combines the excellent spatial resolution and in vivo pathology visualization of PET with the molecular specificity and sensitivity of fluid biomarkers.

Rationale for Integration

Complementary Information

• PET imaging provides:
• Regional distribution of amyloid plaques and neurofibrillary [tau](/proteins/tau) tangles
• Spatial patterns of glucose hypometabolism
• Direct visualization of amyloid and tau pathology in the brain
• Fluid biomarkers provide:
• Quantitative measures of protein abnormalities in the central nervous system
• Dynamic measures that can track disease progression
• Information about neurodegeneration through [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)

Clinical Research Applications

The combination enables researchers to:

Overview

The integration of positron emission tomography (PET) imaging with cerebrospinal fluid (CSF) and blood-based biomarkers represents a cornerstone of modern [Alzheimer's disease](/diseases/alzheimers-disease) (AD) biomarker research. This approach combines the excellent spatial resolution and in vivo pathology visualization of PET with the molecular specificity and sensitivity of fluid biomarkers.

Rationale for Integration

Complementary Information

• PET imaging provides:
• Regional distribution of amyloid plaques and neurofibrillary [tau](/proteins/tau) tangles
• Spatial patterns of glucose hypometabolism
• Direct visualization of amyloid and tau pathology in the brain
• Fluid biomarkers provide:
• Quantitative measures of protein abnormalities in the central nervous system
• Dynamic measures that can track disease progression
• Information about neurodegeneration through [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)

Clinical Research Applications

The combination enables researchers to:

Key Research Findings

Amyloid PET + CSF Biomarkers

Studies presented at AAIC 2026 demonstrated:

• High concordance between amyloid PET positivity and CSF [Aβ42](/proteins/amyloid-beta)/40 ratio (85-95% agreement)
• Discordance patterns provide biological insights - some individuals with positive PET have normal CSF and vice versa
• CSF Aβ42/40 as a reliable screening tool to identify amyloid-positive individuals for PET imaging

Tau PET + CSF p-tau Biomarkers

The relationship between tau PET and CSF phosphorylated tau (p-tau) was a major focus:

• Strong correlation between regional tau PET uptake and CSF p-tau181/p-tau217 levels
• [p-tau217](/biomarkers/p-tau-217) shows particularly high correlation with tau PET in neocortical regions
• Regional specificity - CSF p-tau may detect earlier tau changes than PET

Neurodegeneration Markers

Integration of imaging and fluid biomarkers for neurodegeneration:

• MRI atrophy patterns combined with NfL provide complementary information
• FDG-PET hypometabolism correlates with CSF NfL in advanced disease
• Multimodal markers improve prediction of cognitive decline

AT(N) Classification System

The NIA-AA Research Framework uses biomarker categories[@jack2018]:

| Category | Imaging Biomarkers | Fluid Biomarkers |
|----------|-------------------|------------------|
| A (Amyloid) | Amyloid PET | CSF Aβ42/40, Aβ42 |
| T (Tau) | Tau PET | CSF p-tau181, p-tau217 |
| (N) (Neurodegeneration) | MRI, FDG-PET | CSF/serum NfL, t-tau |

Clinical Profiles

| Profile | Amyloid | Tau | Neurodegeneration |
|---------|---------|-----|-------------------|
| AD | + | + | + |
| AD path, no neurodegeneration | + | + | - |
| Non-AD pathologic change | - | + or - | + |

Implementation Considerations

Cost-Effectiveness Strategies

• Use CSF screening to reduce unnecessary PET scans
• Sequential testing strategies for clinical diagnosis
• Blood-based biomarkers as initial screening tools

Technical Harmonization

• Standardization of CSF assays across laboratories
• PET quantification harmonization (e.g., Centiloid project)
• Cross-platform validation studies

Cross-Linking to NeuroWiki

Related Pages

• [AAIC 2026: Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)
• [AAIC 2026: Imaging Advances](/events/aaic-2026/imaging-advances)
• [Diagnostic Biomarkers in Neurodegeneration](/mechanisms/diagnostic-biomarkers-neurodegeneration)
• [AD Biomarker-to-Mechanism Mapping](/mechanisms/ad-biomarker-mechanism-map)

Biomarker Pages

• [Amyloid PET](/biomarkers/amyloid-pet) - under development
• [CSF Aβ42](/biomarkers/amyloid-beta-42-csf) - under development
• [p-tau181](/biomarkers/p-tau181) - under development
• [p-tau217](/biomarkers/p-tau217) - under development
• [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light-chain-nfl) - under development

References